Literature DB >> 3819480

Pharmacokinetics of amphotericin B in infants and children.

J R Starke, E O Mason, W G Kramer, S L Kaplan.   

Abstract

The pharmacokinetics of amphotericin B (AmB) have not previously been evaluated in children. Five very small, premature infants and five older children received 0.25-1.0 mg of AmB/kg per 24 hr for Candida infections. Serum concentrations of AmB, measured by bioassay, were used to determine various pharmacokinetic parameters of AmB. A one-compartment model of drug distribution was most consistent with the data. The volume of AmB distributed per kilogram of body weight was smaller and the elimination clearance more rapid than those previously reported for adults. Serum levels were approximately one-half those seen in adults given comparable doses. The mean concentrations of AmB after various doses were as follows: at 0.25 mg/kg, 0.08 microgram/ml; at 0.50 mg/kg, 0.20 microgram/ml; at 0.75 mg/kg, 0.42 microgram/ml; and at 1.0 mg/kg, 0.54 microgram/ml. Interpatient variability was, however, marked, especially among the premature infants. AmB pharmacokinetics are different in infants and children than in adults; these differences may have implications for determining optimal pediatric dosing regimens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3819480     DOI: 10.1093/infdis/155.4.766

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

Review 1.  Pharmacokinetics of antifungal agents in children.

Authors:  Kevin Watt; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Early Hum Dev       Date:  2011-02-01       Impact factor: 2.079

Review 2.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

3.  Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers.

Authors:  S W Sanders; K N Buchi; M S Goddard; J K Lang; K G Tolman
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 4.  Zygomycosis in neonates: an uncommon but life-threatening infection.

Authors:  Emmanuel Roilides; Theoklis E Zaoutis; Aspasia Katragkou; Daniel K Benjamin; Thomas J Walsh
Journal:  Am J Perinatol       Date:  2009-04-23       Impact factor: 1.862

5.  Reduction toxicity of Amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major.

Authors:  Tahereh Zadeh Mehrizi; Mehdi Shafiee Ardestani; Ali Khamesipour; Mostafa Haji Molla Hoseini; Nariman Mosaffa; Ali Anissian; Amitis Ramezani
Journal:  J Mater Sci Mater Med       Date:  2018-07-28       Impact factor: 3.896

6.  Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factor.

Authors:  Iftekhar Mahmood
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

7.  Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.

Authors:  T J Walsh; P Whitcomb; S Piscitelli; W D Figg; S Hill; S J Chanock; P Jarosinski; R Gupta; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

8.  Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling.

Authors:  G Robbie; W L Chiou
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

9.  Flow cytometric assay for estimating fungicidal activity of amphotericin B in human serum.

Authors:  E Martin; U Schlasius; S Bhakdi
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

Review 10.  Antifungals in systemic neonatal candidiasis.

Authors:  Daniel A C Frattarelli; Michael D Reed; George P Giacoia; Jacob V Aranda
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.